Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations DOI Creative Commons
Thomas Koeglsperger, Emir Berberovic, Christian Dresel

et al.

Journal of Neural Transmission, Journal Year: 2025, Volume and Issue: unknown

Published: March 22, 2025

Abstract Traditional advanced therapies in Parkinson’s disease (PD) with motor fluctuations and dyskinesias like continuous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel (LCIG), entacapone (LECIG), or deep brain stimulation (DBS) have played a central role managing therapy-related complications. Recently, subcutaneous foslevodopa/foscarbidopa (CSFLI) has emerged as novel therapeutic option. This manuscript provides insights from one year of real-world experience CSFLI, addressing critical questions that clinicians face when selecting the most appropriate therapy for PD. Our discussion centers on key considerations patient selection, exploring which individuals may benefit more CSFLI compared to other device-aided therapies. We highlight CSFLI’s advantages flexibility ease use but also consider limitations, particularly its side effects, such skin-related issues. Recommendations are presented how prevent manage these adverse effects maximize compliance success. Additionally, paper examines strategies optimizing concurrent oral medications combined providing guidance balancing pump necessary adjunctive treatments.

Language: Английский

Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations DOI Creative Commons
Thomas Koeglsperger, Emir Berberovic, Christian Dresel

et al.

Journal of Neural Transmission, Journal Year: 2025, Volume and Issue: unknown

Published: March 22, 2025

Abstract Traditional advanced therapies in Parkinson’s disease (PD) with motor fluctuations and dyskinesias like continuous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel (LCIG), entacapone (LECIG), or deep brain stimulation (DBS) have played a central role managing therapy-related complications. Recently, subcutaneous foslevodopa/foscarbidopa (CSFLI) has emerged as novel therapeutic option. This manuscript provides insights from one year of real-world experience CSFLI, addressing critical questions that clinicians face when selecting the most appropriate therapy for PD. Our discussion centers on key considerations patient selection, exploring which individuals may benefit more CSFLI compared to other device-aided therapies. We highlight CSFLI’s advantages flexibility ease use but also consider limitations, particularly its side effects, such skin-related issues. Recommendations are presented how prevent manage these adverse effects maximize compliance success. Additionally, paper examines strategies optimizing concurrent oral medications combined providing guidance balancing pump necessary adjunctive treatments.

Language: Английский

Citations

0